CMC (Células Mesenquimales Cultivadas)

CMC (Células Mesenquimales Cultivadas) is an advanced therapy medicinal product (ATMP) consisting of autologous or allogeneic bone marrow-derived mesenchymal stem cells (MSCs). Developed by the Instituto de Terapia Regenerativa Tissular (ITRT) in Barcelona, the cells are isolated and expanded over a 21-day period under GMP-compliant conditions. The therapy is designed to facilitate tissue regeneration and modulate inflammatory responses through the cells' innate differentiation potential and the secretion of paracrine immunomodulatory factors. CMC is administered via local injection—such as intra-articular for osteoarthritis, intratendinous for tendinopathies, or intradiscal for lumbar disc disease—and has been utilized in clinical research and under individual patient authorizations from the Spanish Agency for Medicines and Medical Devices (AEMPS) since 2002.

Other names

Cultivated Mesenchymal CellsCMC-ITRTCélulas Mesenquimales Cultivadas